These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 26365141)

  • 1. Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.
    Lozano R; Martinez-Cerdeno V; Hagerman RJ
    Curr Pharm Des; 2015; 21(34):4972-4979. PubMed ID: 26365141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
    Lozano R; Hare EB; Hagerman RJ
    Neuropsychiatr Dis Treat; 2014; 10():1769-79. PubMed ID: 25258535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragile X spectrum disorders.
    Lozano R; Rosero CA; Hagerman RJ
    Intractable Rare Dis Res; 2014 Nov; 3(4):134-46. PubMed ID: 25606363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragile X syndrome: from targets to treatments.
    Wijetunge LS; Chattarji S; Wyllie DJ; Kind PC
    Neuropharmacology; 2013 May; 68():83-96. PubMed ID: 23257237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Targeted Treatments for Fragile X Syndrome.
    Protic D; Salcedo-Arellano MJ; Dy JB; Potter LA; Hagerman RJ
    Curr Pediatr Rev; 2019; 15(4):251-258. PubMed ID: 31241016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragile X syndrome and fragile X-associated tremor ataxia syndrome.
    Hall DA; Berry-Kravis E
    Handb Clin Neurol; 2018; 147():377-391. PubMed ID: 29325626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of inclusions positive for polyglycine containing protein, FMRpolyG, indicates that repeat-associated non-AUG translation plays a role in fragile X-associated primary ovarian insufficiency.
    Buijsen RA; Visser JA; Kramer P; Severijnen EA; Gearing M; Charlet-Berguerand N; Sherman SL; Berman RF; Willemsen R; Hukema RK
    Hum Reprod; 2016 Jan; 31(1):158-68. PubMed ID: 26537920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.
    Olmos-Serrano JL; Corbin JG; Burns MP
    Dev Neurosci; 2011; 33(5):395-403. PubMed ID: 22067669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [FMR1 PREMUTATION CARRIERS - ARE THEY REALLY ASYMPTOMATIC?].
    Elizur S; Berkenstadt M; Ries-Levavi L; Gruber N; Pinhas-Hamiel O; Hassin-Baer S; Raas-Rothschild A; Raanani H; Cukierman-Yaffe T; Orvieto R; Cohen Y; Gabis L
    Harefuah; 2018 Apr; 157(4):241-244. PubMed ID: 29688643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling unusual X-chromosome patterns during fragile-X syndrome genetic testing.
    Esposito G; Tremolaterra MR; Savarese M; Spiniello M; Patrizio MP; Lombardo B; Pastore L; Salvatore F; Carsana A
    Clin Chim Acta; 2018 Jan; 476():167-172. PubMed ID: 29170104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quest for targeted therapy in fragile X syndrome.
    Zeidler S; Hukema RK; Willemsen R
    Expert Opin Ther Targets; 2015; 19(10):1277-81. PubMed ID: 26294013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for Fragile X Syndrome: Progress to Date.
    Davenport MH; Schaefer TL; Friedmann KJ; Fitzpatrick SE; Erickson CA
    Drugs; 2016 Mar; 76(4):431-45. PubMed ID: 26858239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon.
    Hagerman RJ; Hagerman PJ
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():365-381. PubMed ID: 34499526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Triplet expansion cytosine-guanine-guanine: Three cases of OMIM syndrome in the same family].
    González-Pérez J; Izquierdo-Álvarez S; Fuertes-Rodrigo C; Monge-Galindo L; Peña-Segura JL; López-Pisón FJ
    Med Clin (Barc); 2016 Apr; 146(7):311-5. PubMed ID: 26776484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology.
    Grigsby J
    Clin Neuropsychol; 2016 Aug; 30(6):815-33. PubMed ID: 27356167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in fragile X: a model for autism and neurodegeneration.
    Hagerman RJ; Ono MY; Hagerman PJ
    Curr Opin Psychiatry; 2005 Sep; 18(5):490-6. PubMed ID: 16639106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragile X Syndrome: Introduction.
    Reches A
    Methods Mol Biol; 2019; 1942():3-10. PubMed ID: 30900171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health problems in females carriers of premutation in the FMR1 gene.
    Lisik MZ
    Psychiatr Pol; 2017 Oct; 51(5):899-907. PubMed ID: 29289969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.